Showing results (231-240 of 245) with videos related to
Sort By:
Pageof 25
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.Journal of Cancer Research and Clinical Oncology|March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patientsMargherita Rimini, Mara Persano, Toshifumi Tada, et al.Targeted Oncology|March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?Margherita Rimini, Mara Persano, Toshifumi Tada, et al.The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.International Journal of Cancer|November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaFederico Rossari, Toshifumi Tada, Goki Suda, et al.Oncology|January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.European Journal of Cancer (Oxford, England : 1990)|June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsMara Persano, Margherita Rimini, Toshifumi Tada, et al.Oncology|October 13, 2024
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World StudyMara Persano, Andrea Casadei-Gardini, Toshifumi Tada, et al.Liver Cancer|September 19, 2024
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter StudyFederico Rossari, Toshifumi Tada, Goki Suda, et al.Pageof 25